Ocata Therapeutics Inc fka OCAT

[rocky301]

Info is contained in CeoCast disclaimers. The following is from the March 29 newsletter.

"A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. This publication accepts compensation from companies that it features. This newsletter should not be regarded as an independent publication. Our editors may, from time to time, acquire positions in the companies that they cover. This could represent a conflict of interest. The CEOcast newsletter shall be under no obligation to inform readers about its trading activities. CEOcast's editors reserve the right to buy or sell shares in these companies at any time. The following companies, featured in this newsletter, have compensated CEOcast: Seaway Valley Capital, seven thousand five hundred dollars per month and ten million shares of stock, iceWEB, seven thousand five hundred dollars per month in cash, plus seven thousand five hundred dollars in stock per month for a six-month agreement, Urigen Pharmaceuticals, fifteen thousand dollars per month, Xcorporeal, editors of CEOcast purchased one hundred fifty thousand shares of stock at seven dollars per share in a private placement and received options to purchase fifty thousand shares of stock at seven dollars per share, Steel Vault, twelve thousand five hundred dollars per month for a one-year agreement, Global Investor Services, seven thousand five hundred dollars per month and one million two hundred thousand shares of stock for a one year agreement, Hythiam, one hundred ten thousand shares for a one-year agreement; CEOcast received sixty-six thousand shares from previous agreements; editors of CEOcast have also purchased approximately one million four hundred twenty-five thousand shares of the company's stock, Advanced Cell Technologies, fifteen thousand dollars per month."
http://www.ceocast.com/(dpgvcb55wm4gjb55e5sp2rmo)/NewsLetters.aspx?id=494